1/7/2022 8:06:33 AM
Revance Expects Preliminary Q4 RHA Collection Revenue To
be $23.0 Mln And $24.0 Mln
10/11/2021 8:12:15 AM
Revance Launches OPUL, The First-of-its-Kind Relational Commerce Platform For Aesthetic Practices
9/16/2021 8:13:42 AM
Revance To Showcase Data From Phase 3 Trial Evaluating Efficacy, Duration Of Effect And Safety Of DaxibotulinumtoxinA
9/10/2021 8:12:43 AM
Revance Presents Data On RHA Collection Of Dermal Fillers At 2021
Virtual Skin Of Color Update Meeting
5/26/2021 8:28:16 AM
Revance: FDA To Initiate Pre-approval Inspection Of Manufacturing Facility For DaxibotulinumtoxinA By End Of June
4/27/2021 8:17:55 AM
Revance Says First Patient Enrolled For DaxibotulinumtoxinA In Glabellar Lines And Cervical Dystonia By Fosun Pharma
1/7/2021 8:24:40 AM
Revance Maintains Strong Balance Sheet; Reaffirms Its Expectations To Be Funded Into 2023
12/17/2020 8:09:14 AM
Revance Therapeutics Reports Positive Efficacy And Duration Results From Phase 2 Upper Facial Lines Study
12/16/2020 8:37:00 AM
Revance Therapeutics To Relocate Its Headquarters From Silicon Valley's Newark, California, To Nashville, Tennessee.
11/25/2020 8:34:56 AM
Revance : FDA Defers Approval Of DaxibotulinumtoxinA For Injection In Glabellar Lines Due To Travel Restrictions
8/11/2020 8:41:05 AM
Revance Therapeutics Announces Publication Of Two
separate Peer-reviewed Articles In Dermatologic Surgery
5/19/2020 8:07:05 AM
Revance Agrees To Acquire HintMD And Its Proprietary Fintech Platform For Aesthetic Practices